Journal CME

Volume 91, Number 7

SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists

Print this Content

How to Obtain AMA PRA Category 1 Credit™ and ABIM MOC points

  1. Review information on this page.
  2. Read the journal article.
  3. Return to this page and select the "Complete the CME/MOC Process" link.
  4. Login to your myCME account.
  5. If claiming MOC, choose the 'CME & MOC' option and complete the posttest.
  6. Complete the registration / evaluation form.
  7. Print your personalized CME / MOC certificate.

Release Date: July 1, 2024
Expiration Date: June 30, 2025

Estimated Time of Completion: 1 hour

Description

The authors summarize recent data and guidelines regarding the use of sodium-glucose cotransporter 2 inhibitors in heart failure and chronic kidney disease and provide practical guidance for their use in both the general medical clinic and hospital ward.

Learning Objective

Appraise when to consider adding sodium-glucose cotransporter 2 inhibitor therapy to the treatment of chronic heart failure with reduced ejection fraction, chronic heart failure with mildly reduced or preserved ejection fraction, acute heart failure, or chronic kidney disease.

Target Audience

Directed to practitioners in cardiology, cardiovascular disease, family medicine, geriatric medicine, internal medicine, nephrology, and pharmacology.

ACCREDITATION STATEMENT

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

American Medical Association (AMA) 

Cleveland Clinic Foundation Center for Continuing Education designates this journal-based activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Certificate of Participation 

A certificate of participation will be provided to other health care professionals for requesting credits in accordance with their professional boards and/or associations.

American Board of Internal Medicine (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**Please Note** To receive MOC you must select the MOC option during the online credit claiming process and complete the required steps. ABIM MOC points will be reported within 30 days of claiming credit.

Activity Directors, Authors, and Other Contributors

Activity Director

Brian F. Mandell, MD, PhD
Chairman, Department of Academic Medicine, Education Institute,
Professor of Medicine, Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University,
Editor in Chief, Cleveland Clinic Journal of Medicine,
Cleveland Clinic, Cleveland, OH

Co-Activity Directors

Craig D. Nielsen, MD, FACP
Vice Chairman, Department of Internal Medicine;
Associate Professor, Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University, Cleveland, OH;
Governor, Ohio Chapter, American College of Physicians;
Deputy Editor, Cleveland Clinic Journal of Medicine,
Cleveland Clinic, Cleveland, OH

James C. Pile, MD
Department of Hospital Medicine;
Associate Professor, Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University, Cleveland, OH;
Deputy Editor, Cleveland Clinic Journal of Medicine,
Cleveland Clinic, Cleveland, OH

George Thomas, MD, MPH
Director, Center for Blood Pressure Disorders, Department of Kidney Medicine;
Associate Professor, Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University, Cleveland, OH;
Deputy Editor, Cleveland Clinic Journal of Medicine,
Cleveland Clinic, Cleveland, OH

Mary T. Cusick, MS
Executive Editor, Cleveland Clinic Journal of Medicine,
Cleveland Clinic, Cleveland, OH

Authors

Rahul Jaswaney, MD
Fellow, Section of Cardiology,
Lewis Katz School of Medicine
at Temple University, Philadelphia, PA

Samantha Sokoloff, MD
Fellow, Section of Endocrinology, Diabetes and Metabolism,
Lewis Katz School of Medicine
at Temple University, Philadelphia, PA

Val Rakita, MD
Associate Professor of Medicine;
Associate Medical Director, Mechanical Circulatory Support Program;
Director, CardioMEMS Program, Advanced Heart Failure, MCS, and Transplant Cardiology,
Lewis Katz School of Medicine
at Temple University, Philadelphia, PA

Daniel J. Rubin, MD, MSc
Professor of Medicine, Interim Co-Director for the Center for Biostatistics and Epidemiology,
Director of Clinical Research, and Deputy Chief, Section of Endocrinology, Diabetes and Metabolism,
Lewis Katz School of Medicine
at Temple University, Philadelphia, PA

Other Contributors

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Integrity and Independence issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education mitigates all relevant conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they have a relationship which, in the context of their contributions, could be perceived as a potential conflict of interest:

Brian F. Mandell, MD, PhD (Activity Director)
  Consulting, Research: DSMB Horizon Pharma
Daniel J. Brotman, MD
  Research/PI in investigator-initiated study Bristol-Myers Squibb Co.
Adam J. Brown, MD
  Consulting, teaching and speaking Amgen
Abhijit Duggal, MD
  Advisor or review panel participant Alung Technologies
Kristin Highland, MD
  Consulting, teaching and speaking     Acceleron Pharma Inc, Actelion, Bayer Healthcare, Boehringer Ingelheim, United Therapeutics Corporation
  Advisor or review panel participant Boehringer Ingelheim, United Therapeutics Corporation
  Consulting Forsee, Genentech/Roche
David Louis Keller, MD
  Ownership interest (stock, stock options in a publicly
owned company)
Glaxo Smith Kline, Johnson and Johnson, Pfizer
Angelo Licata, MD
  Ownership interest (stock, stock options in a publicly
owned company)
Merck & Co, Inc.
Christian Nasr, MD
  Advisor or review panel participant Horizon Therapeutics, Nevro Corporatio
  Consulting research: principal investigator Siemens
Bernard J. Silver, MD
  Advisor or review panel participant Takeda
Tyler Stevens, MD
  Teaching and speaking Abbvie Pharmaceuticals
  Consulting Boston Scientific
Olaf Wendler, PhD
  Consulting Edwards Lifesciences

All other authors, co-activity directors, reviewers and CCJM staff report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.


(Article opens in a new tab / window; return to this window to complete the activity).

after completion, claim CME

This CME activity was produced by the Cleveland Clinic Journal of Medicine and the Cleveland Clinic Center for Continuing Education.